Oxcarbazepine

Authors: Beydoun A.; Kutluay E.

Source: Expert Opinion on Pharmacotherapy, Volume 3, Number 1, 1 January 2002 , pp. 59-71(13)

Publisher: Informa Healthcare

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Oxcarbazepine (OXC) (Trileptal®, Novartis) is one of the recently introduced anti-epileptic drugs (AEDs) in the US. This drug has demonstrated efficacy as adjunctive therapy in adults and children, and as monotherapy in adults for the treatment of seizures of partial onset. There is also convincing evidence of its efficacy in patients with newly diagnosed and refractory trigeminal neuralgia. In addition, the initial efficacy results of oxcarbazepine in other neuropathic pain conditions and in bipolar disorders are encouraging. In this review, recommendations on the optimal clinical use of OXC are given based on its pharmacokinetic profile, efficacy and tolerability in those various conditions.

Keywords: bipolar disorders; efficacy; epilepsy; mania; neuropathic pain; oxcarbazepine; partial seizures; pharmacokinetics; safety; tolerability; trigeminal neuralgia

Document Type: Drug Evaluation

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$99.00 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A